Zhenghai Biotechnology: Announcement on the progress of the “Double Improvement of Quality and Return” action plan
Announcement on the progress of the "Dual Improvement of Quality and Return" action plan
Securities code: 300653 Securities abbreviation: Zhenghai Biotechnology Announcement number: 2026-042
Yantai Zhenghai Biotechnology Co., Ltd.
Announcement on the progress of the "Dual Improvement of Quality and Return" action plan
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and there are no false records,
Misleading statements or material omissions.
In order to safeguard the interests of all shareholders, enhance investor confidence, and promote the company's sustainable development, the company aims to promote the improvement of company quality and investment value, and has formulated an action plan of "double improvement of quality and return" focusing on focusing on the main business, improving innovation and development capabilities, improving the quality of information disclosure, and strengthening standardized operation levels. For details, please refer to the "Announcement on the "Double Improvement of Quality and Return" Action Plan" disclosed by the company on cninfo.com on March 31, 2026.
During the reporting period, the company actively implemented the “double improvement of quality and return” action plan. The progress is as follows:
1. Deeply cultivate the main business and promote high-quality development of the company
As the earliest high-tech enterprise in the field of regenerative medicine in China, the company focuses on the research and development, production and sales of bio-regenerative materials, and has mature industrial operation capabilities for Class III implantable medical devices. During the reporting period, the company firmly focused on precision marketing and concentrated its superior resources to deeply explore the core business areas. The company's meningeal series products were successfully selected in the Beijing-Tianjin-Hebei "3+N" alliance procurement project. The company continued to do a good job in academic promotion and customer maintenance of terminal medical institutions. The product market share remained stable and the company's core business foundation was consolidated. The calcium-silicon bioceramic oral bone repair material has completed the production conversion and the production link has been opened. The company has simultaneously promoted the market access, academic promotion and commercialization of this product. As of the end of the reporting period, the product has been listed on the provincial network in 25 provinces across the country.
The company actively practices the development path of pharmaceutical manufacturing and digital intelligence integration, actively lays out informatization and digital transformation and upgrading, and realizes the optimization and improvement of the entire chain of R&D, production, management, and operation. During the reporting period, the company was successfully selected into the list of national-level digital transformation typical cases ("Digital Three Products" direction) and won the first batch of Shandong Province advanced smart factory certification in 2026. The above honors are authoritative recognition of the company's comprehensive "intelligent manufacturing" strength and are of great significance in promoting the company's high-quality development.
2. Adhere to innovation-driven and enhance the company’s core competitiveness
The company has long been focused on technological innovation, and has continuously accumulated leading technological core and competitive advantages through deep industry development. During the reporting period, the company actively promoted the research and development of various products. The new product calcium-silicon bioceramic oral bone repair material successfully passed the approval of the State Food and Drug Administration and obtained the "Medical Device Registration Certificate" (registration certificate number: National Medical Device Approval 20263170015). As the first domestic 3D printing, bionic porous structure, and calcium-silicon-based bioceramic oral bone repair material, it realizes new processes, new structures, and new components, providing a new way for the oral cavity.
Announcement on the progress of the "Double Improvement of Quality and Return" action plan to provide personalized solutions for bone defects in complex environments, further enriching the company's dental restoration product line and improving the product matrix. The products under development, uterine cavity repair membrane and breast patch, have respectively obtained the "Acceptance Notice" for medical device registration applications issued by the State Food and Drug Administration and entered the registration review stage. During the same period, the company steadily advanced the registration progress of existing products, successfully completed the renewal registration approval of self-etching adhesives and surgical packing sponges, and completed registration changes to extend the validity period of active biological bone products, increase product specifications, models, and product technical requirements. Through continuous product iteration and compliance optimization, the company further improves the level of refinement of production operations, accurately matches the needs of diversified clinical customers, effectively controls production costs, and comprehensively enhances the market adaptability and comprehensive competitiveness of existing products. During the reporting period, the company invested RMB 23.9981 million in R&D, accounting for 15.02% of the operating income during the same period. As of the end of the reporting period, the company had obtained a total of 94 patents, effectively ensuring the company's product upgrades and development reserves for new products.
3. Consolidate corporate governance and adhere to standardized operations
The company carries out corporate governance work in strict accordance with relevant provisions of laws, regulations, normative documents and the Articles of Association, continues to standardize the operations of shareholders' meetings, the board of directors and special committees, gives full play to the important role of independent directors and special committees of the board of directors in strategic decision-making, audit supervision, risk control, etc., and continuously improves corporate governance efficiency and standardized operation levels.
During the reporting period, the company strictly implemented the relevant requirements for the supervision of listed companies, revised the "Investor Relations Management System", "Raised Funds Management System", "Foreign Investment Management System", "Director Remuneration Management System", "Senior Management Remuneration Management System" and other system contents to further improve the level of corporate governance.
In the future, the company will continue to strictly implement the decision-making procedures of the shareholders' meeting, board of directors and special committees to ensure that all governance entities perform their duties in place; strengthen internal control management in key areas, continue to improve the construction of the internal control system, prevent operating and compliance risks, and build a scientific, transparent and efficient governance operation mechanism.
4. Improve the quality of information disclosure and efficiently convey company value
During the reporting period, the company actively fulfilled its social responsibilities and released the "2025 Social Responsibility Report" to enhance the company's brand image with practical actions. The company strictly abides by relevant laws and regulations on information disclosure, adheres to the principles of true, accurate, complete, timely and fair information disclosure, and does a good job in the disclosure of annual reports and various temporary announcements. During the reporting period, the company took the initiative to hold an online performance briefing for 2025, actively participated in the 2026 online collective reception day event for investors of listed companies in Shandong, fully communicated with investors, and fully demonstrated the company's development strategy, operating results and potential value. The company makes full use of various channels such as the interactive platform, shareholders' meetings, on-site surveys, and investor hotlines to strengthen investor relations management, respond to investor concerns in a timely manner, effectively convey the company's value, and create a good investor relations atmosphere.
5. Pay attention to shareholder returns and share development results
The company attaches great importance to shareholder returns, always puts shareholders' interests in an important position, and shares development results with investors. During the reporting period, the company implemented and completed the 2025 profit distribution plan, distributing a cash dividend of 2.80 yuan (tax included) to all shareholders for every 10 shares, with a total dividend amount of 49,739,186.00 yuan, accounting for approximately 60.36% of the net profit attributable to shareholders of the listed company. Since its listing, the company has realized a cumulative cash dividend of 667 million yuan, which is 2.85 times the amount of funds raised in the IPO.
Announcement on the progress of the "Dual Improvement of Quality and Return" action plan
In the future, the company will continue to strictly fulfill its responsibilities and obligations as a listed company, focus on its main business, continue to strengthen technological innovation and industrialization capabilities, continuously consolidate corporate governance and internal control standards, adhere to the investor-oriented concept, firmly establish the awareness of returning shareholders, continue to actively implement the "double improvement of quality and return" action plan, and actively contribute to stabilizing the market and stabilizing confidence.
Yantai Zhenghai Biotechnology Co., Ltd.
board of directors
August 25, 2026